环化腺苷二磷酸核糖及其在不同细胞中的效应

环化腺苷二磷酸核糖(cyclicADP-ribose,cADPR)作为一种天然化合物可调节细胞内Ca2 的释放,其效应广泛存在于原生质、动物、植物乃至人类,被认为是一种新的胞内信使分子。腺苷二磷酸核糖环化酶和CD38具有双功能酶活性,既可催化生成cADPR,又可对其进行分解。在细胞内cADPR主要是通过ryanodine受体调节Ca2 的释放,而Ca2 又参与细胞的许多重要功能,因此cADPR信号途径的确立可为免疫调节、疾病的介入治疗以及新药研发等方面开辟广阔的研究领域。     

聚腺苷二磷酸-核糖聚合酶1与DNA双链断裂修复的相关性

DNA双链断裂(double strand breaks,DSBs)是细胞最严重的DNA损伤形式。细胞通过同源重组(homologous recombination,HR)和非同源末端连接(non-homologous end joining,NHEJ)途径修复DNA双链断裂损伤。聚腺苷二磷酸核糖基化(poly(ADP-ribosyl)ation,PARylation)是蛋白质翻译后修饰过程,这个过程由聚腺苷二磷酸 核糖聚合酶家族(poly(ADP-ribose)polymerases,PARPs)催化完成。PARP1作为PARPs家族最重要的成员,其在DNA损伤应答方面发挥重要作用。研究显示,PARP1在DSBs修复过程中发挥关键作用,参与DSBs的早期应答反应及其具体修复途径,可依据KU蛋白的存在与否发挥不同的特定作用。本文较全面地综述了PARP1在DNA双链断裂修复方面的潜在作用,将为临床疾病的诊治提供新的思路。     

聚腺苷二磷酸核糖聚合酶抑制剂耐药性研究进展

聚腺苷二磷酸核糖聚合酶（PARP）抑制剂可选择性杀死同源重组功能缺陷的肿瘤细胞，而对正常细胞的危害较小，这是“合成致死” 理论应用于临床的典型范例。尽管 PARP 抑制剂作为一种新型靶向药物，极具应用潜力，但其临床应用也面临诸多问题，其中耐药性的产 生被认为是限制 PARP 抑制剂临床应用的重要原因之一。简介 PARP-1 的功能及 PARP-1 抑制剂研究进展，着重综述 PARP-1 抑制剂耐药 的临床表现、可能的发生机制及逆转策略，为 PARP-1 抑制剂的临床合理应用提供参考。     

多聚二磷酸腺苷聚合酶1与动脉粥样硬化

心血管疾病已经成为发达国家威胁生命的主要疾病,而动脉粥样硬化是最常见的心血管疾病之一．近来研究发现,多聚二磷酸腺苷聚合酶1(PARP1)在动脉粥样硬化致病机理中起着重要的作用．PARP1为PARP家族中含量最丰富的核酶,担负着DNA缺口敏感酶的功能,具有双向作用．正常情况下,它参与DNA损伤的修复,但过量激活则消耗NAD⁺和ATP使细胞功能紊乱,最终坏死．一些疾病的细胞程序性死亡机制可能与此相关,这些疾病包括动脉粥样硬化、冠心病、糖尿病及相关的心血管功能紊乱．有趣的是,除DNA损伤激活PARP1外,最近又发现激酶、多胺、咖啡因代谢物、茶碱和四环素等也可以参与PARP1的调节,核因子(NF-κB)和细胞内Ca²⁺也参与PARP1的调节．本文总结了靶点PARP的生物功能和基本原理,动脉粥样硬化致病的可能机制以及PARP1对其调节的研究进展,将对动脉粥样硬化的研究提供有力帮助．     

腺苷二磷酸核糖基化作用及其机制

腺苷二磷酸核糖基化作用及其机制杨其伟,陈德风（南开大学分子生物学研究所,天津３０００７１）关键词腺苷二磷酸核糖基化作用腺苷二磷酸（ＡＤＰ）核糖基化作用是以ＮＡＤ作为修饰基团的供体,将ＡＤＰ核糖共价连接到受体蛋白上去的一种转译后的修饰过程。自从６０年代...     

PARP的生物学与病理学功能

PARP1是真核细胞内具有多聚腺苷酸二磷酸核糖基（PAR）催化活性的蛋白酶,目前发现18个具有该活性的蛋白．多聚腺苷酸二磷酸核糖基化反应是细胞内进行的翻译后修饰,该修饰作用于许多蛋白,涉及到染色体的稳定,DNA损伤修复,基因转录,细胞的增长,死亡和凋亡等方面．在生理病理方面与炎症,肿瘤,衰老等疾病相关联．本文针对以上方面进行了总结和讨论．     

聚腺苷二磷酸-核糖聚合酶1功能与其抑制剂的作用及耐药机制

聚腺苷二磷酸-核糖聚合酶1(poly ADP-ribose polymerase-1,PARP1)是细胞中重要的修饰酶,其最广为人知的作用是通过自身PAR修饰,募集以XRCC1为首的多种DNA损伤修复效应蛋白质,参与DNA单、双链损伤修复。PARP1还能通过促进复制叉停滞与核小体解聚,为DNA损伤修复提供有利条件,维持基因组稳定性。近年来,除DNA损伤修复方面的作用,还发现PARP1能影响细胞凋亡、自噬与炎症通路,与神经退行性疾病的发生发展密切相关。而PARP抑制剂(PARP inhibitor,PARPi)是一种靶向PARP1,与细胞同源重组(homologous recombination,HR)缺陷表型共同作用,产生合成致死效应的抗肿瘤药物。该药物可捕获PARP1并抑制其活性,一方面直接干扰PARP1参与的DNA损伤修复通路,另一方面也抑制了PARP1介导的DNA损伤修复通路选择和复制叉停滞,使细胞基因组不稳定。然而,在临床治疗中常发现肿瘤细胞对PARPi不敏感。肿瘤细胞对PARPi耐药与自身基因突变高度相关,这些基因分别作用于细胞HR修复途径、PARP1循环途径、复制叉稳定性和药物主动外排等方面,在耐药肿瘤患者中确定具体的突变位点,将为临床治疗提供帮助。本文旨在对PARP1的功能作一综述,并重点介绍PARPi的作用机制和与肿瘤耐药相关的突变基因及其耐药机制,以期加深对细胞中PARP1介导的DNA损伤修复通路的认识,并为将来的临床治疗提供新思路。     

拟南芥多聚ADP核糖聚合酶Ⅰ的原核表达与活性检测

采用RT-PCR技术获得了拟南芥多聚ADP核糖聚合酶[poly(ADP-ribose)polymerase,PARP]PARP1基因的全长cDNA,转入原核表达载体pET32a并转化宿主菌Origami(DE3),加入终浓度为0.3mmol/L IPTG,在16℃下诱导可获得较多的可溶重组蛋白。纯化TRX-PARP1,在反应液中加入NAD+和断裂DNA,通过SDS-PAGE凝胶电泳和Western blotting分析,TRX-PARP1分子量可随着时间的延长逐渐增大,产生向上的弥散,表明蛋白质连上了ADP核糖分子;与此对比,作为参照的标签蛋白TRX无此现象。实验结果显示原核表达拟南芥PARP1能够催化自身多聚ADP核糖化修饰,为深入研究植物多聚ADP核糖聚合酶的功能奠定了基础。     

环腺苷二磷酸核糖（cADPR）—一种新发现的胞内信使分子

环腺苷二磷酸核糖（ｃＡＤＰＲ）──一种新发现的胞内信使分子胡国渊,（中国科学院上海药物研究所新药研究国家重点实验室２０００３１）胡桦（上海医科大学临床医学系２０００３２）多种激素、递质和细胞膜表面对应的受体结合后能引起细胞内钙释放,从而使细胞内游离钙...     

聚腺苷二磷酸核糖基聚合酶──在DNA损伤修复及程序性死亡中的作用

聚腺苷二磷酸核糖基聚合酶(poly (ADP-ribose) polyerase, PARP)是存在于多数真核细胞中的一个蛋白质翻译后修饰酶,它可催化组蛋白H₁等重要核蛋白及它自身的聚腺苷二磷酸核糖基化作用.细胞受到外界损伤因子作用时, DNA发生链断裂,PARP结合到DNA断裂口,其催化活性被激活,修饰受体蛋白,进而引发一系列级联反应.这种性质使PARP有可能作为细胞内的分子感受器和传感器,启动细胞内对损伤作出反应的信号传导机制,从而根据细胞受损程度决定细胞的命运：修复或是死亡．     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.     

肝癌中HBV和HCV基因和抗原的分布及意义

采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细     

Selection with two alleles and complete dominance

For a plant selection model with frequency-independent viabilities, fertilities and selfing rates, it is shown that apart from global fixation, for certain parameter combinations a protected polymorphism and facultative fixation (either allele may become fixed according to initial frequencies) may both occur. Facultative fixation requires different selling rates for the dominant and recessive type. Protection of the polymorphism requires resource allocation for male and female function. In this connection the problem of purely genetically caused population extinction is discussed.
For general frequency dependence and regular segregation, the chances for establishment of a completely recessive gene are compared to those of a completely dominant gene. It is proven that the process of establishment of the recessive gene, despite a fitness advantage, may be considerably endangered by drift effects if random mating prevails. The recessive gene may reach the same effectivity in establishment as a dominant gene, only if the recessive homozygote mates exclusively with its own type during the period of establishment.